C-Rad ABFRA:24C -2.17%90 Quick Ratio is 2.73 as of Mar. 2026, which is 1% below its 10-year median of 2.75. GuruFocus rates FRA:24C with a GF Score™ of 90/100 and a GF Value™ of €2.86 (Fairly Valued). The stock has 4 warning signs investors should review. Among 855 Medical Devices & Instruments companies, C-Rad AB ranks better than 64.8% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. C-Rad AB's quick ratio for the quarter that ended in Mar. 2026 was 2.73.
C-Rad AB has a quick ratio of 2.73. It generally indicates good short-term financial strength.
The historical rank and industry rank for C-Rad AB's Quick Ratio or its related term are showing as below:
FRA:24C'
s Quick Ratio Range Over the Past 10 Years
Min: 1.2 Med: 2.75 Max: 3.91
Current: 2.73
During the past 13 years, C-Rad AB's highest Quick Ratio was 3.91. The lowest was 1.20. And the median was 2.75.
FRA:24C's Quick Ratio is ranked better than 64.8% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 1.86
vs FRA:24C: 2.73
C-Rad AB (FRA:24C) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
C-Rad AB Quick Ratio Related Terms
C-Rad AB Quick Ratio Historical Data
* Premium members only.
The historical data trend for C-Rad AB's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, C-Rad AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C-Rad AB Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, C-Rad AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where C-Rad AB's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
C-Rad AB's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C-Rad AB (FRA:24C) has a Quick Ratio of 2.73 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on C-Rad AB and its competitors. This is near median its historical median of 2.75. Over the past decade, C-Rad AB's Quick Ratio has ranged from 1.20 to 3.91. According to the industry distribution chart, C-Rad AB ranks #301 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 35.2%.
Is C-Rad AB's Quick Ratio too high?
C-Rad AB's current Quick Ratio of 2.73 is near median its 10-year median of 2.75. Over the past 10 years, this metric has ranged from a low of 1.20 to a high of 3.91. The Medical Devices & Instruments industry median Quick Ratio is 1.86. C-Rad AB's value of 2.73 is 46.8% above this industry median. Based on the distribution chart, C-Rad AB ranks #301 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, C-Rad AB has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does C-Rad AB's Quick Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, C-Rad AB ranks #301 out of 855 companies for Quick Ratio. This puts C-Rad AB in the upper half of its industry. The industry median Quick Ratio is 1.86. C-Rad AB's value of 2.73 is 46.8% above this benchmark. Historically, C-Rad AB's own Quick Ratio has ranged from 1.20 to 3.91 over the past decade. While the company's 10-year median is 2.75 vs. the industry median of 1.86, C-Rad AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.86, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C-Rad AB's current Quick Ratio of 2.73 is 46.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on C-Rad AB and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C-Rad AB's current Quick Ratio is 2.73, which is near median its own 10-year median of 2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-Rad AB stock overvalued right now?
Based on GuruFocus' analysis, C-Rad AB (FRA:24C) is currently considered Fairly Valued. The stock's GF Value™ is €2.86, compared to a current price of €3.16 — trading 10.5% above its estimated fair value. The current Quick Ratio is 2.73, which is near median its 10-year median of 2.75 and 46.8% above the Medical Devices & Instruments industry median of 1.86. C-Rad AB's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For C-Rad AB (FRA:24C), the current Quick Ratio is 2.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C-Rad AB (FRA:24C) Overvalued in 2026?
Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued.
The current stock price of €3.16 is trading 10.5% above its estimated GF Value™ of €2.86.
GuruFocus considers C-Rad AB to be Fairly Valued.
Key valuation signals for FRA:24C:
Quick Ratio: 2.73 (near median its 10-year median of 2.75)
GF Value™: €2.86 vs. price of €3.16 (10.5% above fair value)
Industry Position: 46.8% above the Medical Devices & Instruments median (#301 of 855)
No single metric tells the full story. See the FRA:24C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
90GF Score
Get the complete analysis for FRA:24C
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:24C has been successfully added to your 
